Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Page 24 Page 25 Page 26 Page 27 Page 28 Page 29 Page 30 Page 31 Page 327 RESEARCH In today’s data-driven environment, winning policy debates depends on compelling, objective information. To that end, AdvaMed sponsored and leveraged studies from prestigious research organizations – including Battelle, the Pacific Research Institute, Ernst & Young, and the National Center for Policy Analysis – as well as AdvaMed member surveys in 2014 and 2015, to help quantify the device tax’s damaging effects. These effects included reduced R&D and delayed patient access to innovation. On the positive side, survey respondents indicated repeal would allow renewed investments in innovation. The findings were disseminated widely to members of Congress, the administration, the media and other health policy influencers. MEDIA OUTREACH Throughout the repeal effort, AdvaMed’s Public Affairs department expanded its range and use of multimedia to spread the word about the negative consequences of the tax and the positive value of medtech innovation – innovation the device tax put at risk. These efforts included creating compelling fact sheets, infographics, ads, videos and social media posts; helping to place op-eds and editorials by member company execs and others in key publications nationwide; and running print and on-line ads in influential Capitol Hill journals. In 2015, AdvaMed launched the United4Innovation campaign to amplify our message with new information, resources and allies, including a web portal that helped generate tens of thousands of letters from repeal supporters to Capitol Hill. STATE EVENTS AdvaMed’s grassroots advocacy included taking our repeal campaign on the road and hosting events at member companies across the country to raise awareness about the effects of the tax on local economies, often with participation by members of Congress and other elected officials. Such events – in key states like Arizona, California, Colorado, Illinois, Indiana, New York, North Carolina, Ohio, Pennsylvania and Wisconsin – helped to educate and engage employees and policymakers alike, and increased the ranks of those able to speak with one voice on the urgent need for device tax relief. House Majority Leader Kevin McCarthy (second from right) meets with AdvaMed Capitol Hill fly-in participants to discuss device tax repeal, including Walter Rosebrough of Steris, AdvaMed Chair Vince Forlenza of BD, Dr. Michael Leong of the Stanford Pain Management Center, Nadim Yared of CVRx, Karen Prange of Boston Scientific, and Mike Genau of Medtronic. Caroll Neubauer, chairman and CEO of B. Braun Medical (at left) joins a device tax repeal rally in Philadelphia organized by state life science trade association Pennsylvania Bio, along with Pennsylvania congressmen Charlie Dent, Patrick Meehan and Ryan Costello, and PA Bio’s Christopher Molineaux, president and CEO (at right). Medical Device Tax Would Be Suspended For Two Years In Tax Deal Medical Device Tax Is Killing Jobs, Depressing Innovation Repealing Tax Has Bipartisan Appeal  Spending Deal’s Adjustments To Health Law Seen As Step To Permanent Change